By AstraZeneca
Additional Protection May Be Needed for This High-Risk Population
The COVID-19 pandemic has had a significant impact on vulnerable groups, particularly the immunocompromised. Vaccines have helped lower hospitalization rates and deaths among the general population, yet immunocompromised individuals remain at heightened risk for severe outcomes from the virus.
Although they make up less than 3 percent of the adult population in the U.S., immunocompromised individuals are responsible for over 40 percent of COVID-19 breakthrough infections, according to research. This trend underscores the necessity for enhanced protective measures for these patients.
Health professionals emphasize the importance of additional strategies for safeguarding immunocompromised patients. Thanks to advancements in technology and science, there are now more treatment options for this vulnerable demographic that can complement existing vaccines.
Immunocompromised individuals are defined as those with weakened immune systems due to various factors, including active cancer treatments, untreated HIV infections, or the use of immunosuppressive medications.
These patients often do not generate adequate immune responses to vaccines, necessitating additional layers of protection. Research indicates that many may not achieve effective immunity after vaccination, thus using antivirals or other therapeutic interventions could be beneficial.
Dr. Brian Koffman of the Chronic Lymphocytic Leukemia Society states that it is critical to provide comprehensive protective measures for immunocompromised individuals. In his view, additional therapies can empower these patients to engage more fully with their communities.
Monoclonal antibodies represent a potential avenue for immunocompromised patients. Unlike vaccines, these laboratory-engineered antibodies do not rely on a fully functional immune system for efficacy. Instead, they can act as replacements, mimicking the immune response to combat specific viruses.
Monoclonal antibodies are currently under investigation for various infectious diseases, including COVID-19, and have shown promise in providing protection for vulnerable populations.
Health experts recommend that immunocompromised individuals consult their healthcare providers regarding the viability of adding monoclonal antibody therapy to their vaccine regimen as a preventive measure against COVID-19.
Why It Matters
Understanding the unique challenges faced by immunocompromised patients during the pandemic is crucial for developing tailored health strategies. By exploring additional treatment options, healthcare providers can better protect these high-risk populations, ultimately aiming to reduce infection rates and improve health outcomes.
—
The content is paid for and supplied by the advertiser. The Washington Post newsroom was not involved in the creation of this content.